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1. Introduction
Tongue squamous cell carcinoma (SCC) is one of the most
common head and neck cancers. Prognosis is associated with
clinical stage, particularly nodal status. Therefore, the expression
of metastasis-related factors such as matrix metalloproteinases,
syndecans, and vascular endothelial growth factor predicts the
treatment outcome of patients with tongue SCC [1–4]. Tongue SCC
is associated with inflammation in the oral cavity, which is
mediated by chronic trauma such as smoking, alcohol consump-
tion, and periodontal disease and is associated with oral
carcinogenesis [5]. Moreover, inflammation promotes cancer
development and progression through its effects on the tumor
microenvironment [6]. Inflammatory mediators and specific cell
types influence the migration, invasion, and metastasis of tumor
cells [6]. Therefore, efficacious therapies must be developed for
targeting inflammation in patients with cancer.
Interleukin (IL)-33 is a member of the IL-1 family and functions
as a ligand for ST2, which is a member of the IL-1 receptor family.
IL-33 is expressed by many cell types, including epithelial cells,
endothelial cells, smooth muscle cells, fibroblasts, and activated
macrophages [7]. In contrast, mast cells (MCs), Th2 cells,
eosinophils, basophils, epithelial cells, and endothelial cells
express ST2 [8–12]. Unlike other members of the IL-1 family,
the cleavage site for caspases is located within the IL-1-like domain
of IL-33, and the cleavage products are biologically inactive.
Biologically active, full-length IL-33 is released when cells sense
inflammatory signals or undergo necrosis. Therefore, IL-33 acts as
an endogenous danger signal or ‘‘alarmin’’ [8,13,14]. Binding of
extracellular IL-33 to ST2 preferentially induces Th2-type immune
responses with concomitant expression of Th2-associated cyto-
kines [7]. It is clear that the potency of IL-33 for activating several
immunocytes probably impacts inflammation. For example, IL-33
is expressed by patients with chronic gastritis, chronic hepatitis,
and inflammatory bowel disease [15–17]. Inflammatory diseases
increase the risk of developing cancer, suggesting that IL-33 may
play an important role in cancer pathogenesis [18,19].
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A B S T R A C T
Objective: The aim of this study was to clarify the role of IL-33 in tumor progression.
Methods: Surgical specimens from 81 patients with squamous cell carcinoma of the tongue were studied
using immunohistochemistry. Primary tumor sections were analyzed for IL-33 and ST2 expression. To
examine the influence of IL-33 on the microenvironment of the tumor, we determined the mast cell
density (MCD) and microvessel density of the stroma.
Results: Patients with high IL-33 expression had a significantly worse prognosis (p = 0.004). IL-33
expression was significantly elevated in patients with local and nodal recurrence (p = 0.014 and
p = 0.019). ST2 expression was also associated with a worse prognosis (p = 0.024) and was significantly
elevated in patients with nodal recurrence (p = 0.004). MCD was associated with worse prognosis
(p = 0.038) and correlated significantly with IL-33 expression (r = 0.626, p < 0.001). Micovessels in the
stroma were significantly increased in the high IL-33 group (p < 0.001).
Conclusion: These data suggest that the IL-33/ST2 axis contributes to tumor aggressiveness and affects
the tumor microenvironment. Immunohistochemical evaluation of IL-33 and ST2 is useful for identifying
patients at a high risk for poor prognosis.
! 2014 Elsevier Ireland Ltd. All rights reserved.
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IL-33 affects the phenotype of cell types that express the
transmembrane isoform of ST2. The inflammatory component of
a neoplasm may include a diverse leukocyte population, and ST2
is expressed on many of these inflammatory cells, including
MCs, macrophages, dendritic cells, eosinophils, and neutrophils
[8,20]. Among the inflammatory cells in the stroma of the tumor,
MCs are important because they secrete cytokines and
chemokines, and influence the phenotypes of other cells through
these soluble mediators as well as through cell–cell interaction.
Moreover, MCs reside in the connective tissue surrounding
tumors, and the accumulation of MCs is often associated with
poor prognosis [21,22]. IL-33 is a potent activator of MCs and
induces their degranulation and maturation, promotes survival,
and induces the production of several proinflammatory cyto-
kines [9,23]. Therefore, it is reasonable to assume that IL-33
contributes significantly to the malignant potential of tumor
cells through the formation of an inflammatory tumor microen-
vironment.
We reported the carcinogenic role of activation-induced
cytidine deaminase (AID), which is induced by an inflammatory
environment [24]. However, the expression of AID does not
correlate with the progression of tongue SCC, which diverted our
attention to IL-33. Inflammation mediated by tobacco smoking,
which is associated with tongue SCC, induces the expression of
IL-33/ST2 in mice [25]. In the present study, we determined the
expression of IL-33 in patients with tongue SCC using immuno-
histochemistry and assessed the relationship between the
expression of IL-33 and prognosis of tongue SCC. Furthermore,
to evaluate the influence of IL-33 on the tumor microenvironment,
we determined the density of MCs in the stroma surrounding
the tumor.
2. Materials and methods
2.1. Patients and specimens
This study included 81 patients who were diagnosed with
tongue SCC. Informed consent was obtained from all patients
in accordance with our institutional guidelines. The patient
characteristics are presented in Table 1. Their clinical status was
determined according to the TNM classification system of the
Union Internationale Contre le Cancer [26]. All patients underwent
surgery at the Division of Otolaryngology-Head and Neck Surgery,
Kanazawa University Hospital between 1982 and 2007. Resection
of the primary tongue tumor was performed in all patients, and
neck dissection was performed in 53 patients with clinically
positive nodes or tumors that were more advanced than stage T2.
The 22 patients with positive margins or pathologically positive
lymph node metastasis underwent postoperative treatment,
including radiotherapy. The mean follow-up period was 50.7
months (median, 41 months; range, 1–131 months). Disease-free
survival was calculated from the date of treatment until the time of
local recurrence or the detection of metastases, including recurrence
in the neck lymph nodes.
2.2. Immunohistochemical analysis
All specimens were the primary tumors. They were fixed in 10%
formalin solution and embedded in paraffin. Serial 3-mm-thick
sections were cut from each block, dewaxed, and rehydrated.
Antigen retrieval was performed by heating slides for 30 min in
citrate buffer (pH 6.0) at 90 8C, cooling for 20 min, and washing.
Endogenous peroxidase was quenched with methanol and 3% H2O2
for 10 min, followed by incubation with Protein Block Serum
(DakoCytomation, Glostrup, Denmark) to decrease nonspecific
binding. Then, the sections were incubated overnight at 4 8C with
primary antibodies against IL-33 (diluted 1:100, rabbit polyclonal,
Medical & Biological Laboratories, Nagoya, Japan), ST2 (diluted
1:100, mouse monoclonal, Medical & Biological Laboratories), mast
cell tryptase (diluted 1:1000, mouse monoclonal, Dako), and CD34
(diluted 1:50, mouse monoclonal, Dako). The sections were
incubated with secondary antibodies conjugated to a peroxi-
dase-labeled polymer (EnVisionTM+ system, Dako) at room
temperature for 30 min. Immune complexes were detected using
3,30-diaminobenzidine tetrahydrochloride, and the sections were
counterstained with hematoxylin. The specificities of the staining
reactions were confirmed using nonimmune serum instead of the
primary antibody.
Table 1
Relationship between clinicopathological features and expression of IL-33, ST2, and MCD.
Characteristic Samples Number of high IL-33
expression (%)
p Number of high ST2
expression (%)
p Number of high
MCD (%)
p
Sex Male 50 24 (48.0) 0.550 25 (50.0) 0.888 25 (50.0) 0.888
Female 31 17 (54.8) 16 (51.6) 16 (51.6)
Age 260 40 17 (42.5) 0.149 20 (50.0) 0.913 21 (52.5) 0.738
>60 41 24 (58.5) 21 (51.2) 20 (48.8)
Histologic type WD 70 37 (52.9) 0.349 37 (52.9) 0.349 36 (51.4) 0.756
MD/PD 11 4 (36.4) 4 (36.4) 5 (45.5)
T classification T1 + T2 67 32 (47.8) 0.379 32 (47.8) 0.379 32 (47.8) 0.379
T3 + T4 14 9 (64.3) 9 (64.3) 9 (64.3)
N classification pN0 62 32 (51.6) 0.798 34 (54.8) 0.198 35 (56.5) 0.070
pN1-3 19 9 (47.4) 7 (36.8) 6 (31.6)
Stage I + II 55 25 (45.5) 0.176 26 (47.3) 0.381 27 (49.1) 0.689
III + IV 26 16 (61.5) 15 (57.7) 14 (53.8)
Local recurrence Negative 71 32 (45.1) 0.014* 34 (47.9) 0.312 35 (49.3) 0.737
Positive 10 9 (90.0) 7 (70.0) 6 (60.0)
Nodal recurrence Negative 61 26 (42.6) 0.019* 25 (41.0) 0.004* 25 (41.0) 0.004*
Positive 20 15 (75.0) 16 (80.0) 16 (80.0)
Distant metastatic recurrence Negative 78 38 (48.7) 0.241 40 (51.3) 0.616 39 (50.0) 1.000
Positive 3 3 (100.0) 1 (33.3) 2 (66.7)
WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated.
* Significance.
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2.3. IL-33 and ST2 expression and mast cell density (MCD)
Two investigators with no prior knowledge of the clinical data
assessed the microvessel counts and expression of IL-33, ST2, and
tryptase.
Staining results for IL-33 and ST2 were classified by estimating
the percentage of tumor cells showing specific immunoreactivity.
Two areas with a high density of stained cells were selected in a
40! field, following which the number of immunoreactive cells
and the total number of tumor cells were counted in two areas in a
200! field. The percentage of positive cells calculated as an
average of two counts was used as the expression score. The
antibody against tryptase was used to determine MCD in the
stroma surrounding the tumor and was classified by estimating the
percentage of tryptase-positive cells in the stroma. The two areas
with the highest MCD were identified in a 200! field. Then, the
number of tryptase-positive cells and the total number of stromal
cells were counted in these areas in a 400! field. To correlate these
results with prognosis, the expression scores and MCD values were
divided into high and low groups using median scores as cutoff
values.
2.4. Microvessel density (MVD)
MVD was calculated by counting the number of vessels stained
with CD-34 according to Weidner et al. [27]. Three areas with the
highest MVD were selected in a 40! to 100! field. Then,
microvessels were counted in the three areas in a 200! field.
MVD was calculated as the average of three counts. Any brownish-
staining endothelial cell or endothelial cell cluster was considered
as a single microvessel.
2.5. Statistical analysis
IBM SPSS Statistics version 19 (IBM, Armonk, New York, USA)
was used for data analysis. The clinical characteristics of patients in
terms of IL-33 and ST2 expression and MCD were analyzed using
Fisher’s exact test and the chi-square test. The relationship
between IL-33 and ST2 expression and MCD was evaluated using
Spearman’s rank correlation coefficient. Survival curves were
evaluated using the Kaplan–Meier method, and differences
between curves were analyzed using the log-rank test. IL-33
expression in relation to MVD was analyzed using the Mann–
Whitney U test. A p value of <0.05 was considered statistically
significant.
3. Results
3.1. IL-33 and ST2 expression
IL-33 was detected only in the nuclei of normal epithelial cells,
and ST2 was observed most frequently, but faintly, in the
membrane and cytoplasm of cells in the prickle cell to horny
layers (Fig. 1A and 1B). In contrast, IL-33 was detected in the nuclei
and cytoplasm of SCC cells (Fig. 1C). ST2 expression was most
prominent in the membrane and cytoplasm of the tumor cells
(Fig. 1D). IL-33 and ST2 expression were observed in 100% and
95.1% of the samples, respectively. The mean expression scores for
IL-33 and ST2 in the tumor cells were 41.59 " 23.89% and
22.14 " 19.29%, respectively.
3.2. MCD
MCs were detected by staining with the anti-tryptase antibody
in all samples, and they were located in the stroma at the margins
of the tumors (Fig. 1E). The mean MCD was 12.54 " 11.60%.
3.3. Correlation of IL-33 and ST2 expression with MCD
IL-33 expression correlated significantly with ST2 expression
(r = 0.558, p < 0.001, Fig. 2A). IL-33 expression also correlated with
MCD (r = 0.626, p < 0.001, Fig. 2B).
3.4. Association of IL-33 and ST2 expression and MCD with disease-
free survival
To evaluate the prognostic value of IL-33 and ST2 expression
and MCD in patients with tongue SCC, patients were stratified
Fig. 1. Immunohistochemical analysis of IL-33 and ST2 expression in normal epithelial and tumor cells (A–D) and tryptase (E) and CD34 (F) expression (original magnification
!200).
(A) IL-33 is detected in the nuclei of normal epithelial cells. (B) ST2 is faintly detected in the membrane and cytoplasm of normal epithelial cells. (C) IL-33 is detected in the
nuclei and cytoplasm of tumor cells. (D) Intense staining of ST2 in the membrane and cytoplasm of tumor cells. (E) MCs were detected as dark-brown stained cells using an
anti-tryptase antibody. They were also located in the stroma at the tumor margins. (F) CD34 expression in vascular endothelial cells (stained dark brown) in the stroma of the
tumor.
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into high and low groups as described in Methods. The median
expression scores for IL-33 and ST2 were 46% and 14%,
respectively, and 9% for MCD. These scores were used as cutoff
values. Of the 81 specimens, 41 were assigned to the high group.
Kaplan–Meier survival analysis revealed that the prognosis was
poorer for the high IL-33 and ST2 groups than for the low IL-33
and ST2 groups (p = 0.004 and 0.024, respectively, Fig. 3A and B).
Similarly, the disease-free survival rate was significantly lower in
the high MCD group than in the low MCD group (p = 0.038,
Fig. 3C).
Furthermore, to examine the relationship of the prognosis of
the high IL-33 patients with postoperative adjuvant therapy,
Kaplan–Meier survival analysis was performed. Of the 41
patients assigned to the high IL-33 group, 14 patients
underwent postoperative radiotherapy. Although the patients
with postoperative treatment tended to have better prognosis
than those without postoperative treatment, there was no
significant difference between the two (p = 0.145 data not
shown).
3.5. Relationship between clinicopathological features and expression
of IL-33, ST2, and MCD
The relationship between immunohistochemical data and
clinicopathological factors of the 81 patients, including age, sex,
T classification, N classification, clinical stage, local recurrence,
nodal recurrence, and distant metastatic recurrence was evaluated
using Fisher’s exact test and the chi-square test (Table 1). Local
recurrence was significantly more frequent among patients in the
high IL-33 group than among those in the low IL-33 group. IL-33
and ST2 expression and MCD were significantly associated with
nodal recurrence. A higher frequency of nodal recurrence
associated significantly with the high IL-33, ST2, and MCD groups,
but not with the low groups. There were no other significant
differences in clinicopathological features between the low and
high IL-33, ST2, and MCD groups.
3.6. Relationship between IL-33 expression and MVD
Vascular endothelial cells reacted specifically with the antibody
against CD34. The microvessels were detected as scattered
structures in the stroma of the tumor (Fig. 1F). MVDs in all
patients ranged from 7 to 75 (mean, 34.41 " 16.46). The correlation
between IL-33 expression and MVD is shown in Table 2. MVD was
significantly higher in the high IL-33 group than in the low IL-33
group (p < 0.001).
4. Discussion
Little is known about the role of IL-33 in the pathogenesis and
progression of carcinomas [18,19]. This is the first study, to our
knowledge, that demonstrates IL-33 expression in tongue SCC and
suggests its role in the progression of this tumor. We detected the
expression of IL-33 and ST2 in patients with tongue SCC by
immunohistochemistry and found that the expression of IL-33 was
significantly correlated with poor prognosis.
We do not go further for the molecular mechanism which is
attributable to the prognostic value of IL-33 in this study, however,
one of the possible mechanism for IL-33-mediated malignant
progression could be an activation of ST2 downstream signal
transduction such as nuclear factor-kB (NF-kB). The IL-33/ST2 axis
leads to activation of NF-kB [8,20,28], which is a key inducer of
innate immunity and inflammation and has emerged as an
important endogenous tumor promoter [6,29]. NF-kB activates
the expression of genes encoding inflammatory cytokines, adhe-
sion molecules, enzymes of the prostaglandin-synthesis pathway,
inducible nitric oxide synthase, and angiogenic factors. Thus,
activation of NF-kB through the IL-33 signaling pathway may
cause cancer progression.
Th2-type responses induced by IL-33 may contribute to tumor
progression. An induction of IL-33 enhances Th2 immune response
and polarizes naı¨ve T cells to produce IL-5 and IL-13 independently
of IL-4 [8,20]. High levels of Th2 cytokines are observed in the
tumor microenvironment and peripheral blood of patients with
certain cancers [30]. Moreover, analysis of ST2-deficient mice
demonstrates that the Th2-associated immune response is
inhibited in the absence of IL-33/ST2 signaling, leading to delayed
induction of mammary tumors and slower tumor growth and
progression [31,32].
In addition, IL-33 induces angiogenesis and vasopermeability
[33]. Our present study reveals that IL-33 expression strongly
correlated with MVD and was significantly associated with local
and nodal recurrence, but not clinical stage. These results suggest
that IL-33 influences the malignant potential of the tumor through
the promotion of angiogenesis and activation of ST2 signaling.
Fig. 2. Correlation between IL-33 and ST2 expression and MCD in tongue SCC.
(A) Correlation between IL-33 and ST2 expression. IL-33 expression correlated
significantly with ST2 expression (Spearman’s rank correlation coefficient). (B)
Correlation between IL-33 expression and MCD. IL-33 expression correlated
significantly with MCD.
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We also demonstrate that IL-33 expression significantly corre-
lated with MCD, suggesting that IL-33 contributes to tumor
progression by activating MCs. An induction of IL-33 potently
activates the innate immune system by inducing pro-inflammatory
cytokines and chemokine production through the activation of MCs.
It also induces the degranulation of IgE-primed MCs and enhances
their maturation and survival [8,20]. The MCD generally correlates
with poor outcome in patients with tongue SCC [34,35]. Further-
more, other studies reveal that IL-33 activates macrophages,
dendritic cells, eosinophils, and neutrophils [8,20]. These cells play
important roles in enhancing an inflammatory environment that
promotes tumor growth in the surrounding tissue [6]. IL-33 may
recruit these inflammatory cells to the stroma of the tumor,
subsequently enhancing tumor aggressiveness.
In conclusion, the high expression level of IL-33 is a risk factor
for poor prognosis in patients with tongue SCC. In the high IL-33
patients, postoperative radiotherapy tended to improve the
prognosis. Those patients that received postoperative radiotherapy
were likely to have poor prognosis. Therefore, this result suggests
that postoperative radiotherapy may be effective in the treatment
of the high IL-33 patients with positive margins or pathologically
positive lymph node metastasis.
IL-33 and ST2 may represent therapeutic targets for tongue SCC.
Although it remains unclear how IL-33/ST2 axis contributes to
tumor progression; our findings indicate that the IL-33/ST2 axis
promotes the malignant potential of tumor by affecting the tumor
as well as its microenvironment. Further investigation is needed to
define the role of IL-33 in malignant potential.
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